Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2

NCT02170389 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02170389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02170389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2
Lead sponsor
Roswell Park Cancer Institute
Phase
Not applicable
Overall status
Terminated
Start date
October 14, 2014
Completion date
March 17, 2017
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent renal cell carcinoma, stage i renal cell cancer, stage ii renal cell cancer